GNS Co-Founder Iya Khalil weighed in on how using AI and big data will transform medicine.

Panel Discussion at BIO conference 2022: Why the FDA will bet more on in silico simulations to trigger better success rates for NDAs.

Big pharma executives and an academic ex- pert weighing the challenge at the BIO International Convention said June 14 they see another tool slowly gaining traction with the potential to decrease timelines and boost chances for approval: in silico modeling.

Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022…

For potentially life-saving drugs and treatments, the road to commercialization is steep. Virtualizing the clinical trial is listed as a tech trend to accelerate drugs discovery and development. As per CB Insights, “In silico techniques will cut the time and money it takes to develop a drug and insulate clinical trials from disruptions…

Pharmaceutical Executive reporter discusses how a coalition of data, computational power, and AI is bringing the full potential of in silico medicine out of the realm of science fiction. Read the full story here.

Precision Oncology News reporter discusses Gemini and its prospective impact on multiple myeloma. Read more here.

Myeloma Research News covers GNS launch of Gemini. Read more here.

This is the first AI-based virtual patient for multiple myeloma, said Colin Hill, the Cambridge, Mass.-based company’s co-founder and chief executive. It is traditionally difficult to predict how specific drugs or combinations of drugs might help individual multiple...